CU6.AX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 14:10):

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults...

Stats
今日成交量	2.95M
平均成交量	999 191
市值	1.38B
EPS	$0 ( 2023-08-24 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-42.33
ATR14	$0.0180 (0.36%)

音量相关性

長: 0.07 (neutral)

短: 0.20 (neutral)

Signal:(46.366) Neutral

Clarity Pharmaceuticals 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Clarity Pharmaceuticals 相关性 - 货币/商品

0.18
( neutral )

0.40
( neutral )

0.00
( neutral )

-0.16
( neutral )

-0.17
( neutral )

-0.22
( neutral )

Clarity Pharmaceuticals 财务报表

Annual	2023
营收:	$9.80M
毛利润:	$9.70M (98.97 %)
EPS:	$-0.0945

FY	2023
营收:	$9.80M
毛利润:	$9.70M (98.97 %)
EPS:	$-0.0945

FY	2022
营收:	$6.46M
毛利润:	$6.41M (99.28 %)
EPS:	$-0.0956

Financial Reports:

No articles found.

Clarity Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.